Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21552223 | 1.00 | TYMP (0.52) | TYMPNT5E | |
| SCHEMBL21552277 | 0.90 | TYMP (0.52) | TYMP | |
| SCHEMBL21552279 | 0.90 | TYMP (0.52) | TYMP | |
| SCHEMBL21552314 | 0.86 | TYMP (0.47) | TYMPNT5E | |
| SCHEMBL21552315 | 0.86 | TYMP (0.47) | TYMPNT5E | |
| SCHEMBL26647620 | 0.86 | TYMP (0.54) | TYMPNT5E | |
| SCHEMBL21552268 | 0.84 | TYMP (0.53) | TYMPNT5E | |
| SCHEMBL21552269 | 0.84 | TYMP (0.53) | TYMPNT5E | |
| SCHEMBL5954788 | 0.83 | TYMP (0.61) | TYMP | |
| SCHEMBL17747092 | 0.83 | TYMP (0.51) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12397013-B2 | Extrahepatic delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240358738-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2024-10-31 | — | — | US | disclosed |
| US-12005074-B2 | Extrahepatic delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240009225-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2024-01-11 | — | — | US | disclosed |
| US-20220307024-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| EP-3983077-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | Alnylam Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3790970-A1 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020257194-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2019217459-A1 | EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220307024-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | SNRPE, AGO2, IGF2BP2 | TYMP 1147/4885NT5E 993/4885 |
| US-20240358738-A1 | EXTRAHEPATIC DELIVERY | RNASE1, SLC10A1, FABP1 | TYMP 760/4885NT5E 1004/4885 |
| US-12005074-B2 | Extrahepatic delivery | RNASE1, SLC10A1, FABP1 | TYMP 760/4885NT5E 1004/4885 |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | RNASE1, LDLR, HAVCR2 | TYMP 995/4885NT5E 977/4885 |
| US-20240009225-A1 | EXTRAHEPATIC DELIVERY | RNASE1, SLC10A1, FABP1 | TYMP 760/4885NT5E 1004/4885 |
| US-12397013-B2 | Extrahepatic delivery | RNASE1, LDLR, HAVCR2 | TYMP 995/4885NT5E 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.